SCCM Podcast

SCCMPod-564 CCE: Endotoxin Activity and Precision Medicine in Septic Shock

·38 min·3 clips
Dr. John Kellum discusses a septic shock endotype with 60% mortality, driven by high endotoxin activity.
Marilyn Bullitt hosts a discussion with Dr. John A. Kellum. Kellum is identified as a professor of medicine and director for the Center for Critical Care Nephrology at the University of Pittsburgh. The conversation centers on endotoxin activity in septic shock. It asks what the EAA test can add to clinical understanding. Kellum describes enrichment for the target. He also describes enrichment for the likelihood of benefit. The discussion ties those ideas to precision medicine. Kellum refers to a completed clinical trial called TIGRIS. The trial uses Bayesian analysis to understand possible survival benefit at 28 days and 90 days. The results were released in abstract form and presented at meetings. Kellum reports a posterior probability of benefit above 95% at both time points. The conversation then moves to the test's practical uses. Absorption therapy with polymyxin B hemoabsorption is described as not yet available in the United States and Canada. That limitation affects how EAA could guide therapy in those settings. Kellum still sees value in knowing whether a patient has a 60% or 12% likelihood of death. He suggests that this kind of prognostic information could influence decisions. Bullitt asks about familiar measures of severity, including lactate and baseline ventilation. The discussion notes that about 59% of patients had lactate greater than two and 20% were on a ventilator at baseline. It also considers the overlap between high EAA, high lactate, and endotoxic septic shock.

As heard by us

A careful review of how endotoxin activity may refine prognosis and treatment selection in septic shock.

Endotoxin activity gives this episode its clearest way into septic shock, with Marilyn Bullitt and Dr. John A. Kellum weighing what the EAA test can tell clinicians about prognosis and possible treatment selection.

Read the full review in PlayNext →

Why you'd press play

Press play when familiar sepsis markers leave you wanting a clearer read on septic shock risk and who might benefit from targeted treatment.

Read the full recommendation in PlayNext →
Listen to the show on